JP2023535027A5 - - Google Patents

Info

Publication number
JP2023535027A5
JP2023535027A5 JP2023504298A JP2023504298A JP2023535027A5 JP 2023535027 A5 JP2023535027 A5 JP 2023535027A5 JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023535027 A5 JP2023535027 A5 JP 2023535027A5
Authority
JP
Japan
Prior art keywords
optionally substituted
cycloalkyl
heterocycle
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535027A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042489 external-priority patent/WO2022020424A1/en
Publication of JP2023535027A publication Critical patent/JP2023535027A/ja
Publication of JP2023535027A5 publication Critical patent/JP2023535027A5/ja
Priority to JP2026020484A priority Critical patent/JP2026097841A/ja
Pending legal-status Critical Current

Links

JP2023504298A 2020-07-21 2021-07-21 ピルビン酸キナーゼを活性化するための組成物及び方法 Pending JP2023535027A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026020484A JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054478P 2020-07-21 2020-07-21
US63/054,478 2020-07-21
PCT/US2021/042489 WO2022020424A1 (en) 2020-07-21 2021-07-21 Compositions and methods for activating pyruvate kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026020484A Division JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2023535027A JP2023535027A (ja) 2023-08-15
JP2023535027A5 true JP2023535027A5 (cg-RX-API-DMAC7.html) 2024-07-03

Family

ID=79728915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504298A Pending JP2023535027A (ja) 2020-07-21 2021-07-21 ピルビン酸キナーゼを活性化するための組成物及び方法
JP2026020484A Pending JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026020484A Pending JP2026097841A (ja) 2020-07-21 2026-02-10 ピルビン酸キナーゼを活性化するための組成物及び方法

Country Status (7)

Country Link
US (1) US20230374017A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185293A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023535027A (cg-RX-API-DMAC7.html)
CN (1) CN116249531A (cg-RX-API-DMAC7.html)
AU (1) AU2021311597B2 (cg-RX-API-DMAC7.html)
CA (1) CA3183980A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022020424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
CN118434720A (zh) 2021-12-22 2024-08-02 西特瑞治疗有限公司 作为丙酮酸激酶调节剂的酞嗪衍生物
WO2023211999A1 (en) * 2022-04-29 2023-11-02 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137320A1 (en) * 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
US8563580B2 (en) * 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
ES2620634T3 (es) * 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
EP2968323A4 (en) * 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3668513B1 (en) * 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US12233063B2 (en) * 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Similar Documents

Publication Publication Date Title
JP2023506410A5 (cg-RX-API-DMAC7.html)
JP2019520417A5 (cg-RX-API-DMAC7.html)
TW536401B (en) A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
JP2005527622A5 (cg-RX-API-DMAC7.html)
JP6087367B2 (ja) 三環式化合物、それらを含む組成物およびそれらの使用
JP2021535112A5 (cg-RX-API-DMAC7.html)
KR20190133047A (ko) Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도
JP2018048183A (ja) 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
CA3006189A1 (en) Comt inhibiting methods and compositions
JP2023513797A5 (cg-RX-API-DMAC7.html)
JP2016525104A5 (cg-RX-API-DMAC7.html)
MX2008011965A (es) Composicion de combinacion farmaceutica comprendiendo al menos un inhibidor de pkc y al menos un inhibidor de jak cinasa para tratar desordenes autoinmunes.
CN106572989A (zh) 用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂
JP2019502686A5 (cg-RX-API-DMAC7.html)
JP2016074699A (ja) プロセス
JP2024522183A5 (cg-RX-API-DMAC7.html)
JP2024504927A5 (cg-RX-API-DMAC7.html)
JP2024511057A5 (cg-RX-API-DMAC7.html)
CA2608463C (en) Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
IL321852A (en) Medication bracelets for the treatment of eye disorders
CN114681458B (zh) 治疗多发性硬化症的方法
JP2007513948A5 (cg-RX-API-DMAC7.html)
JP2005525377A (ja) デスメチルセレジリンの投与による末梢神経障害の予防および処置のための方法
RU2007111704A (ru) 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения
CN102272126A (zh) 光学纯喹唑啉类化合物